FBDIX: Franklin Biotechnology Discovery A

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

FBDIX Franklin Biotechnology Discovery A

  • Fund
  • FBDIX
  • Price as of: Dec 10, 2019
  • $161.61
    + $1.62 + 1.01%

Profile

FBDIX - Profile

Vitals

  • YTD Return 32.1%
  • 3 Yr Annualized Return 5.3%
  • 5 Yr Annualized Return -1.6%
  • Net Assets $1.08 B
  • Holdings in Top 10 51.1%

52 WEEK LOW AND HIGH

$161.61
$112.89
$162.18

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.02%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 28.62%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000
  • IRA $250

Fund Classification


Distributions

  • YTD Total Return 32.1%
  • 3 Yr Annualized Total Return 7.7%
  • 5 Yr Annualized Total Return 2.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.67%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 15, 1997
  • Shares Outstanding
    N/A
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan S. McCulloch

Fund Description

The Franklin Biotechnology Discovery Fund Class A (FBDIX) is an actively managed fund that specializes in the health care sector. FBDIX specifically targets those biotech companies engaged in new drug development and marketing. This includes firms in genomics research, genetic engineering and gene expression therapy. Managers use a bottom-up, fundamental approach to picking biotech stocks for FBDIX’s assets and lean heavily on stocks with competitive profiles and large market opportunities for their drugs.

Fees for FBDIX are considered low. However, given its specialized nature, the fund is only suitable as a satellite position. The fund is internally managed by Franklin Advisers.


Get Updates About FBDIX

Sign up for Advisor Access to receive email updates about FBDIX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 32.1% 9.8% 47.8% 5.98%
1 Yr 16.4% -15.7% 26.6% 8.55%
3 Yr 5.3%* -12.3% 24.7% 69.09%
5 Yr -1.6%* -10.9% 14.5% 63.81%
10 Yr 11.0%* -1.9% 17.8% 31.82%

* Annualized

Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.6% -25.3% 21.5% 90.09%
2017 16.0% -10.8% 43.9% 51.38%
2016 -20.7% -31.6% 6.9% 77.36%
2015 -3.0% -20.4% 13.8% 60.19%
2014 28.6% -5.8% 31.5% 10.42%

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 32.1% 9.8% 47.8% 5.98%
1 Yr 16.4% -15.7% 35.3% 10.26%
3 Yr 7.7%* -12.3% 27.2% 67.27%
5 Yr 2.3%* -10.9% 16.6% 59.05%
10 Yr 15.6%* -1.9% 17.9% 25.00%

* Annualized

Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.6% -25.3% 22.2% 90.99%
2017 18.8% -10.8% 45.8% 56.88%
2016 -17.1% -26.4% 8.7% 73.58%
2015 5.7% -16.6% 15.2% 56.31%
2014 33.8% -5.8% 36.7% 14.58%

NAV & Total Return History


Holdings

FBDIX - Holdings

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Assets 1.08 B 3.25 M 47.5 B 49.61%
Number of Holdings 75 26 388 56.69%
Net Assets in Top 10 554 M 913 K 17.4 B 35.43%
Weighting of Top 10 51.14% 21.3% 77.1% 27.56%

Top 10 Holdings

  1. Amgen Inc 8.10%
  2. Vertex Pharmaceuticals Inc 6.80%
  3. Gilead Sciences Inc 6.12%
  4. Biogen Inc 5.21%
  5. Illumina Inc 4.80%
  6. Reata Pharmaceuticals Inc A 4.61%
  7. GW Pharmaceuticals PLC ADR 4.25%
  8. Regeneron Pharmaceuticals Inc 4.05%
  9. Iovance Biotherapeutics Inc 3.88%
  10. Alexion Pharmaceuticals Inc 3.31%

Asset Allocation

Weighting Return Low Return High FBDIX % Rank
Stocks
97.85% 90.21% 103.54% 53.54%
Cash
1.98% 0.00% 9.79% 36.22%
Other
0.17% -27.41% 5.17% 30.71%
Preferred Stocks
0.00% 0.00% 1.08% 24.41%
Convertible Bonds
0.00% 0.00% 1.54% 18.11%
Bonds
0.00% 0.00% 20.60% 18.11%

Stock Sector Breakdown

Weighting Return Low Return High FBDIX % Rank
Healthcare
97.76% 56.22% 99.75% 40.16%
Energy
0.09% 0.00% 0.43% 1.57%
Utilities
0.00% 0.00% 0.00% 10.24%
Technology
0.00% 0.00% 16.35% 44.88%
Real Estate
0.00% 0.00% 5.81% 18.90%
Industrials
0.00% 0.00% 2.40% 21.26%
Financial Services
0.00% 0.00% 5.93% 32.28%
Communication Services
0.00% 0.00% 1.02% 14.17%
Consumer Defense
0.00% 0.00% 34.83% 20.47%
Consumer Cyclical
0.00% 0.00% 10.49% 18.90%
Basic Materials
0.00% 0.00% 1.94% 32.28%

Stock Geographic Breakdown

Weighting Return Low Return High FBDIX % Rank
US
88.97% 58.61% 99.93% 20.47%
Non US
8.88% 0.00% 40.52% 79.53%

Expenses

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.02% 0.10% 4.94% 68.38%
Management Fee 0.59% 0.09% 1.30% 16.54%
12b-1 Fee 0.25% 0.00% 1.00% 20.83%
Administrative Fee 0.15% 0.01% 0.40% 55.36%

Sales Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 2.50% 5.75% 53.85%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 28.62% 0.00% 341.00% 19.49%

Distributions

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank
Dividend Yield 0.00% 0.00% 3.95% 25.98%

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Income Ratio -0.67% -2.24% 2.12% 76.92%

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

FBDIX - Fund Manager Analysis

Managers

Evan S. McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

22.22

22.2%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Steven Kornfeld


Start Date

Tenure

Tenure Rank

Sep 15, 2015

4.21

4.2%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

1.25

1.3%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.22 9.78 19.59